2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor
  5. P2Y14 Receptor Isoform

P2Y14 Receptor

 

P2Y14 Receptor Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium salt
    		Agonist 99.83%
    Uridine 5’-diphosphoglucose (UDP-glucose) disodium salt, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium salt is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium salt is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
  • HY-114364
    UDP-Galactose disodium
    		Agonist 99.42%
    UDP-Galactose disodium is a natural agonist of the P2Y14 receptor with an EC50 of 0.67 μM for the hP2Y14 receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major.
  • HY-113044
    Uridine diphosphate glucose
    		Agonist
    Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR1.
  • HY-161727
    P2Y14R antagonist 1
    		Antagonist
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.
  • HY-150524
    UDP-Galactose
    		Agonist
    UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for Gi protein-conjugated P2Y14 receptors in the immune system (IC50=0.67 μM, hP2Y14).
  • HY-162661
    P2Y14R antagonist 2
    		Antagonist
    P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active P2Y14R antagonist with an IC50 value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis.
  • HY-161343
    HDL-16
    		Antagonist
    HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function.